Medications for Treatment of Opioid Use Disorder among Persons Living with HIV.
Curr HIV/AIDS Rep
; 16(1): 1-6, 2019 02.
Article
en En
| MEDLINE
| ID: mdl-30684117
ABSTRACT
PURPOSE OF REVIEW Recent HIV outbreaks have occurred as a result of the current US opioid epidemic. Providing medications for opioid use disorder (MOUD) with methadone, buprenorphine, and extended-release naltrexone is essential to achieving optimal HIV treatment outcomes including viral suppression and retention in treatment. This review describes the pharmacology of MOUD with specific attention to interactions with antiretroviral therapy, and to the effect of MOUD on HIV treatment outcomes. RECENT FINDINGS:
Methadone and buprenorphine both improve HIV viral suppression, adherence to antiretroviral therapy, and overall mortality for persons with opioid use disorder (OUD). Extended-release naltrexone has been most extensively studied in persons with HIV leaving incarcerated settings, and improves HIV viral suppression in that context. Strategies that integrate MOUD and HIV treatment are crucial to optimize viral suppression. The differing pharmacokinetic and delivery characteristics of these MOUD offer diverse options. Given the chronic and relapsing nature of both HIV and OUD, long-term approaches are required.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Buprenorfina
/
Metadona
/
Naltrexona
/
Trastornos Relacionados con Opioides
Tipo de estudio:
Etiology_studies
Límite:
Humans
Idioma:
En
Año:
2019
Tipo del documento:
Article